PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27520370-0 2016 Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway. Niclosamide 18-29 EPH receptor B2 Homo sapiens 121-124 27520370-2 2016 Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway. Niclosamide 18-29 EPH receptor B2 Homo sapiens 170-173 27520370-6 2016 Importantly, niclosamide inhibits phosphorylation of Erk, Mnk1 and eIF4E in CML cells. Niclosamide 13-24 EPH receptor B2 Homo sapiens 53-56